Technology Transfer Center of the National Cancer Institute
Get Connected
with TTC
Complete the
form and we'll respond as soon as possible and add your information to our Marketing database for future opportunities.
Get Co-Development announcements automatically!
Your information will not be used for any other purposes.
Join our LinkedIn Group
Follow Us on TwitterVelcade®
NIH's (NCI) Contribution
- Conducted preclinical studies for Velcade®
- Developed a formulation with a longer, stable shelf life
Industrial Partners' Contribution
- Myogenetics synthesized the active ingredient for Velcade®
- ProScript conducted preclinical oncology studies in collaboration with institutions including the NCI, NIH
- Millennium Pharmaceuticals initiated the clinical trials that resulted in FDA approval
Results of Collaboration
- Product -- Anti-cancer drug Velcade®
- FDA approved Velcade® as treatment for refractory multiple myeloma, which accounts for 2% of all cancer deaths each year
- Velcade® is being clinically tested against ovarian, colon, pancreatic, lung, and prostate cancers, as well as leukemia and non-Hodgkin's lymphoma
